# A Study to Evaluate Role of Inhaled Amikacin to Prevent Ventilator Associated Pneumonia in Patients With Cirrhosis

> **NCT06808074** · PHASE4 · RECRUITING · sponsor: **Asian Institute of Gastroenterology, India** · enrollment: 162 (estimated)

## Conditions studied

- Hepatic Encephalopathy
- Cirrhosis
- Ventilator Associated Pneumonia (VAP)

## Interventions

- **DRUG:** Inhaled amikacin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06808074
- **Lead sponsor:** Asian Institute of Gastroenterology, India
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-12
- **Primary completion:** 2026-02
- **Final completion:** 2026-05
- **Target enrollment:** 162 (ESTIMATED)
- **Last updated:** 2025-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06808074

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06808074, "A Study to Evaluate Role of Inhaled Amikacin to Prevent Ventilator Associated Pneumonia in Patients With Cirrhosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06808074. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*